Prevalence of gastrointestinal malignancy in iron deficiency without anaemia: A systematic review and meta-analysis by Alexandre, Leo et al.
 
 
Title: Prevalence of gastrointestinal malignancy in iron deficiency 
without anaemia: a systematic review and meta-analysis  
 
Short title: Iron deficiency and gastrointestinal cancer 
 
Authors and affiliations: Leo Alexandre1,2, Charelle Manning2, Simon S M Chan*1,2 
1Norwich Medical School, University of East Anglia, Norwich, UK, NR4 7TJ  
2Department of Gastroenterology, Norfolk and Norwich University Hospital, Norwich, UK, NR4 
7UY  
 
Declaration of interest: None 
 
Abbreviations: CI, confidence interval; GI, gastrointestinal; IDA, iron deficiency anaemia; 
IDWA, iron deficiency without anaemia; NSAID, non-steroidal anti-inflammatory drug; NNS, 
number needed to scope 
 
*Correspondence: Dr Simon Chan, Department of Gastroenterology, Norfolk and Norwich 
University Hospital, Norwich, UK, NR4 7UY. E-mail: simon.chan@nnuh.nhs.uk 
 
Author contributions: All authors participated in the research and preparation of the 
manuscript. Concept and design of study (LA, SSMC), data collection (LA, CM, SSMC), data 
analysis and interpretation (LA, CM, SSMC), drafting of the manuscript (LA, SSMC), critical 






Background: Iron deficiency anaemia is associated with gastrointestinal (GI) malignancy and 
is an indication for GI investigations. However, the relevance of iron deficiency without 
anaemia (IDWA) and the underlying risks of GI malignancy are uncertain.  Therefore, the aim 
of this study was to estimate the prevalence of GI malignancy in patients with IDWA overall 
and in clinically relevant subgroups. 
 
Methods: We searched MEDLINE and EMBASE for studies that reported on the prevalence or 
risk of GI malignancy in patients with confirmed IDWA. We performed a random effects meta-
analysis of proportions and assessed statistical heterogeneity using the I2 statistic.  
 
Results: A total of 1923 citations were screened and 5 studies (4 retrospective cohorts, 1 
prospective cohort) comprising 3329 participants with IDWA were included in the meta-
analysis. Overall pooled random-effects estimates for prevalence of GI malignancy in those 
with IDWA were low (0.38%, 95% CI 0.00%–1.84%, I2=87.7%). Older patients (2.58%, 95% CI 
0.00%–8.77%); non-screening populations (2.45%, 95% CI 0.16%–6.39%) and men and post-
menopausal women (0.90%, 95% CI 0.11%–3.23%) with IDWA were at increased risk of GI 
malignancy compared to younger patients (0.00%, 95% CI 0.00%–0.21%); screened 
populations (0.24%, 95% CI 0.00%–1.10%) and pre-menopausal women (0.00%, 95% CI 
0.00%–1.05%).  
 
Conclusion: Overall IDWA is associated with a low risk of GI malignancy. Older patients and 
non-screening populations are at elevated risk and require GI investigations. Those not in 
these subgroups have a lower risk of GI malignancy and may wish to be monitored following 










Gastrointestinal (GI) cancers are the most common malignancy worldwide, leading to over 1.6 
million deaths per annum[1]. The significant burden from this disease and its association with 
iron deficiency anaemia (IDA), particularly in those of an older age[2-4], has led to national 
guidelines recommending further investigation of the GI tract in the presence of IDA[5-8]. 
Unlike IDA, there is little consensus regarding the need for further investigations in those with 
iron deficiency without anaemia (IDWA), despite this being a common haematological finding 
often noted on routine blood tests.  The prevalence of IDWA is four times as common as IDA 
with population cohort studies estimating that 1 in 20 adults have an IDWA[9]. Yet the 
relevance of IDWA and the underlying risks of GI malignancy are uncertain. As a proportion of 
IDWA may progress to IDA, one study suggests that all those with IDWA should undergo 
further GI investigations[10]. Others tentatively recommend further investigations only in 
those with IDWA and ‘higher risk profiles’ following discussion of the risks and benefits[6].  
 
Therefore, the aim of this systematic review and meta-analysis was to determine the 
prevalence and quantify the risk of GI malignancy in those with IDWA overall and according 
to clinically relevant subgroups. As gastroscopy and colonoscopy are invasive GI investigations 
with associated risks, this will enable informed clinician and patient decision making for those 







The protocol for this systematic review was registered on the PROSPERO database 
(www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42019127611) and conducted 
in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) guidelines[11].  
 
Search strategy 
We sought relevant published articles and abstracts by searching MEDLINE and EMBASE (both 
from 1/1/2000 onwards) (appendix 1) using the OVID interface, and manual searches of 
reference lists of any systematic reviews identified by the previous step. We used the 
following search terms (including related terms) to search each database: iron deficiency, 
oesophagus, stomach, small bowel, colon, and carcinoma. No language restrictions were 
placed on the searches. Searches were up to date as of 5 December, 2019. 
 
Eligibility criteria 
Only cross-sectional or cohort studies satisfying the following eligibility criteria were included 
in the systematic review: (i) at least one adult patient group with confirmed IDWA - no 
restrictions were placed on the definition of iron deficiency given a lack of a universally 
applicable definition[12], however the definition was required to be presented for eligibility; 
(ii) the article presented sufficient data to calculate the proportion with IDWA diagnosed with 
a GI malignancy. No restrictions were placed on the populations studied, whether screening 
or symptomatic, the GI investigations undertaken (if any) or the interval between diagnosis of 
IDWA and GI investigation. Aside from confirmed IDWA, disease cohorts were ineligible for 
inclusion. Two reviewers (LA and SSMC) independently screened abstracts and selected full 
text articles for inclusion based on the above criteria. Discrepancies were resolved through 




Data extraction and quality assessment  
Two reviewers (LA and SSMC) independently extracted data from each selected article for 
study characteristics (study population, study design, setting, location, recruitment period, 
sample size, ‘normal’ haemoglobin definition, iron deficiency definition, investigations 
performed, indication for blood tests, prevalence definition, number of GI malignancies 
detected in the study population); patient characteristics (mean age, gender, ethnicity, 
prevalence of: menstruation, smoking, alcohol, vegetarianism, veganism and non-steroidal 
anti-inflammatory use); the number of patients with IDWA and of these, the number 
diagnosed with GI malignancy. Two reviewers (LA and SSMC) used a modified Newcastle 
Ottawa Scale for cross-sectional studies[13] adapted for the purpose of this systematic 
review, to appraise the internal validity of selected studies (Supplementary appendix 2). Using 
this scale, studies were scored across three domains: selection (three questions); 
comparability and outcome (one question each). Assessment for questions relating to sample 
size and statistical analysis were omitted as they were deemed not applicable to the research 
question. Therefore, for individual studies the highest possible score was eight points. 
Discrepancies were resolved through consensus discussion between reviewers. We contacted 
authors for additional information where required. 
 
Statistical analysis  
The primary outcome was a composite of any GI malignancy (oesophageal, gastric, small 
bowel or colorectal). We used the STATA program, metaprop[14], to perform a meta-analysis 
of proportions extracted from each study. Presented confidence intervals for individual 
studies were calculated using the binomial exact method[15]. Proportions were transformed 
to stabilize their variances using Freeman-Tukey double arcsine transformation[16], prior to 
calculation of pooled estimates using the random effects model proposed by DeSimonian and 
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Laird[17]. Confidence intervals for the pooled estimates were calculated using the Wald 
method. We estimated the percentage of variation across all studies due to heterogeneity, 
rather than chance, using I2; with values of 25%, 50% and 75% respectively indicating low, 
moderate and high heterogeneity. To quantify risk of GI cancer in clinically relevant 
subgroups, and explore heterogeneity, pre-specified subgroup analyses were conducted by 
screening status, age, and menopausal status. Heterogeneity between subgroups was 
determined (P values for heterogeneity <0.1 were regarded as statistically significant).  
 
We determined the Number Needed to Scope (NNS) as the number of individuals required to 
undergo GI investigations to detect one case of GI malignancy[18] i.e. the reciprocal of the 
prevalence of GI malignancy based on our meta-estimates. This was calculated overall and per 
subgroup (screening status, age, and menopausal status). 
   






Results of systematic review 
Search and selection of studies  
Among 1923 unique articles identified from the literature search, twenty-eight full-text 
articles were assessed for eligibility, of which five were ultimately eligible for inclusion[9, 10, 
19-21] (Figure 1). The twenty-three excluded articles were excluded on the basis of existing 
disease (six studies)[22-27], or an absence of patients with IDWA (seventeen studies)[28-44].  
 
Study characteristics  
The characteristics of selected studies are shown in table 1. Four were retrospective cross-
sectional studies and one was a prospective cross-sectional study. Of the four retrospective 
cross-sectional studies, two were performed in Europe (Spain and Belgium)[20, 21], one in  
South Korea[10] and one in Israel[19]. The sole prospective cross-sectional study originated 
from the United States of America[9]. Three studies were conducted in hospital-based settings 
in asymptomatic and symptomatic patients[10, 20, 21] with the remaining two studies 
conducted in a nationwide cohort (NHANES)[9] and a population of young male army recruits 
up to the age of 30 years[19]. Three of the studies consisted of participants that had blood 
tests to assess for iron deficiency and anaemia, as part of a routine medical screening[9, 10, 
19]. In total, 3329 participants were recruited and assessed across all studies with the largest 
study comprising of 1858 participants[19].  Three studies defined a normal haemoglobin (Hb) 
as Hb ≥ 13 g/dL in men or Hb ≥ 12g/dL in women[10, 20, 21].  The study in male army recruits 
defined a normal Hb as ≥ 14 g/dL[19] whilst the NHANES study defining a normal Hb as being 
greater than the fifth percentile[9]. Three studies defined iron deficiency as either a ferritin ≤ 
50 mcg/l[21] or ≤ 20mcg/l[19, 20] with one of these studies also accepting a transferrin 
saturation < 15% as an indicator of iron deficiency regardless of ferritin[19]. The NHANES 
study based iron deficiency exclusively on an iron saturation < 15%[9] and a single study 
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defined iron deficiency as a combination of ferritin ≤ 50 ng/ml and total iron binding capacity 
≥ 300mg/dl[10]. The prevalence of GI malignancy (excluding adenomas) was defined in the 
NHANES study, the population of asymptomatic young male army recruits and study from 
Spain as a GI malignancy within less than 2 years, up to 3 years and within 1 year, respectively, 
following detection of IDWA.  Gastroscopy and colonoscopy in all participants as 
investigations for GI malignancy in the context of IDWA was only done in two studies[10, 20]. 
The remaining studies investigated IDWA utilizing a combination of gastroscopy, colonoscopy 
and/or imaging (CT/MRI/capsule) without stating the exact number or proportion of 
participants who had undergone these investigations for their IDWA[9, 19, 21]. 
 
Patient characteristics 
The mean age of recruited participants between studies was between 21 to 83 years (table 
2). Of all recruited participants, 72% were male. Only one study excluded patients with 
menorrhagia, vegetarianism and non-steroidal anti-inflammatory drugs (NSAIDs)[10].   
 
Study outcomes  
The risk of GI malignancy in IDWA ranged between 0 – 1.8% for four studies whilst a single 
study set in a geriatric hospital-based population reported the risk of GI malignancy in IDWA 
as 15%. Notably, the actual number of cases (n=3) and participants (n=20) in this particular 
study were small[21]. Few studies stratified the risk of GI malignancy in those with IDWA 
based on age. In the NHANES study, all cases of GI malignancy in those with IDWA were at 
least ≥ 50 years. Similarly, in the study performed in Spain the only case of colorectal cancer 
in IDWA was found in a participant ≥ 70 years. However, in the same study a pedunculated 
gastric polyp in a female < 50 years was subsequently found to have adenocarcinoma 
infiltrating the stalk[20]. The study of asymptomatic young men with IDWA appeared to have 
no risk of GI malignancy[19]. Similarly, sub-analyses by the NHANES I study reported that the 
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risk of GI malignancy in pre-menopausal women was lower (0.00%; 95% CI 0.00% – 1.05%) 
than that of men and post-menopausal women (0.90%; 95% CI 0.11% to 3.23%). 
 
Results of the meta-analysis 
All five studies from the systematic review were included in the meta-analysis with a total of 
13 GI malignancies found in 3329 participants (Figure 2). Overall, the random-effects 
estimates for the prevalence of GI malignancy in those with IDWA were low (0.38%; 95% CI 
0.00% – 1.84%) with high heterogeneity (I2 = 87.7%). Meta-analysis of studies that had 
sufficient subgroup data allowing stratification by age showed that the prevalence of GI 
malignancy in those with IDWA is predominantly in those who are older (≥ 50 years of age) 
(2.58%; 95% CI 0.00% – 8.77%)[9, 20, 21] with little risk in those < 50 years (0.00%; 95% CI 
0.00% – 0.21%)[9, 19, 20]. Meta-analysis of screened populations showed that the prevalence 
of GI malignancy in IDWA is lower (0.25%; 95% CI 0.00% - 1.10%) than that of non-screened 
populations (2.45%; 95% CI 0.16 % - 6.39%). 
 
Overall, the NNS was 263 (95% CI 54 - ∞). Stratifying by age we found that the NNS in those ≥ 
50 years was 39 (95% CI 11 - ∞) and in those < 50 years was ∞ (95% CI 476 - ∞). For screened 
populations the NNS was 417 (95% CI 91 - ∞) and for non-screened populations was 41 (95% 
CI 15 - 625) with the NNS for premenopausal women, and men and post-menopausal women 
being ∞ (95% CI 95 - ∞) and 111 (95% CI 31 - 909) respectively. 
 
Study quality and risk of bias 
Based on our modified Newcastle-Ottawa Scale (appendix 2) studies assessed scored between 
5 and 7 (maximum score = 8). One study received a score of 7[9], three studies received scores 
of 6[10, 19, 20] and one study scored 5[21]. Only two studies were truly representative of the 
wider population[9, 10] with the remaining three studies focused on those who were 
11 
 
elderly[21], asymptomatic young and male[19], or had been referred to secondary care for 
gastroscopy and colonoscopy[20]. The possibility of selection bias was deemed to be low 
provided the findings from these three studies were applied to similar populations. Three 
studies had participation rates of 100%[10, 19, 20] whilst the two remaining studies either 






There is a lack of consensus on whether IDWA requires further investigation. To the best of 
our knowledge, the present analysis is the first to systematically review the prevalence of GI 
malignancy in those with IDWA and to quantify the risk of those most likely to have malignant 
GI pathology. Our results show that the overall risk of GI malignancy is low in those with IDWA. 
However, this risk is elevated in those of an older age (≥ 50 years) and non-screening 
populations. These findings would suggest that these subgroups of patients should have their 
IDWA investigated further, whilst those not in these categories may wish to be kept under 
observation instead of proceeding to GI investigations following discussion of the risks and 
potential benefits of such procedures.  
 
This systematic review has several limitations that stem from shortcomings and uncertainties 
from included studies. The clinical relevance of IDWA as an indication for endoscopic 
investigation is best considered in asymptomatic individuals, since GI symptoms, independent 
of IDWA, may prompt further investigation regardless of IDWA status. While predominantly 
asymptomatic individuals will be very likely to contribute to screening populations[10, 19] and 
in the setting of a population-based cohort study[9], the same cannot be assumed for two of 
the included hospital-based studies[20, 21], where the prevalence of GI symptoms is relevant 
and not reported. This may have resulted in an overestimate of the prevalence of GI 
malignancy overall and separately in the older and younger groups. The interval between 
diagnosis of IDWA and GI investigation (and/or the end of follow-up) was not reported in three 
of the studies[9, 19, 20]. It is therefore uncertain whether a reasonable time period was 
applied in order to define the malignancy as prevalent.  In line with current definitions of 
interval cancers of either the upper or lower GI tract[45], we propose an interval of three 
years as reasonable. Caution should be applied when attempting to generalize these findings 
to other patient groups and should consider the varying characteristics of the included study 
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populations. This will likely have contributed to the substantial heterogeneity (I2 = 87.7%) 
observed for the overall meta-estimate. Nevertheless, the overall prevalence of GI malignancy 
was very low. Interpretation of clinically important subgroups (stratification by age, gender 
and menopausal status) should be informed by an understanding of the studies contributing 
to these groups and the precision of the meta-estimates. The younger, male subgroup were 
predominantly informed by a cross-sectional study of young male recruits to the Israel 
defence force (n= 1858)[19], followed by a subgroup contributing to NHANES I (n= 420)[9]. 
Iron deficiency is very common in male army recruits participating in strenuous exercise 
programs and has similarly been observed in elite athletes[46, 47]. Nevertheless, estimates 
from these two studies were similar (no GI cancers developed in either group), and the pooled 
prevalence of GI malignancy in younger patients was very low with high degree of precision 
(0.00%, 95% CI 0.00% – 0.21%). As expected, the prevalence of malignancy in older patients 
with IDWA was higher, however the estimates were imprecise (2.58%, 95% CI 0.00 – 8.77%). 
This uncertain estimate was mainly driven by a selective and small (n=20) cohort of older 
(mean age 82.8 years) hospital inpatient and outpatients[21]. There is a relative paucity of 
data to inform the prevalence of GI malignancy in pre-menopausal women and men and post-
menopausal women, which were subgroups drawn from the same study[9].  
 
We therefore recommend the conduct of further generalizable cross-sectional population-
based studies to more reliably inform the need for GI investigation in patients with IDWA. In 
particular, precise estimates of the prevalence of GI malignancy in relevant asymptomatic 
patient subgroups (stratified simultaneously by age groups, and gender) are required, with 
explicit reasoned definition of the interval between detection of IDWA and 
investigation/follow-up. Future research should also assess the role of non-invasive testing to 
further risk-stratify those with asymptomatic IDWA and guide selection for endoscopic 
investigations. In the appropriate contexts, these may include tissue transglutaminase, faecal 
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calprotectin and faecal immunochemical testing (FIT). Such investigations may be prudent in 
order to minimise the number of unnecessary invasive endoscopic investigations in the 
context that IDWA is a common finding[9]. Certainly, FIT testing is already being explored to 
aid selection for colonoscopy in the work-up for IDA[34, 48, 49]; and while its diagnostic 
accuracy has been established in a range of populations[50], its performance, stratified by age 
and gender, is understudied; and its utility in patients with IDWA is currently unknown.  
 
CONCLUSIONS 
In summary, the observational evidence suggests that the prevalence of GI malignancy overall 
in patients with IDWA is low; however, it appears to be elevated in older and non-screening 
populations. Our meta-estimates may inform patient and clinician decision making with 
regards to the appropriateness of further endoscopic investigation in those with IDWA 
particularly those who are considered low risk. There is a paucity of data to inform the risk 
according to gender and in post-menopausal women. More population-based research is 
required to further refine estimates and inform clinical practice.  
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